Skip to main content

Table 3 Assessment of pain

From: Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review

Publication

Assessment tool

Time after SBRT (Change of pain in % of patients compared to the number of patients reporting pain at baseline)

Comito (2017)

NRS

1 month improvement in 82% (62% analgesics suspended, 10% analgesics reduced by 50%, 10% analgesics reduced by 20%)

3 months improvement in 82% (62% analgesics suspended, 10% analgesics reduced by 50%, 10% analgesics reduced by 20%)

Gurka (2013)

QLQ-PAN26

directly after radiotherapy improvement 50%, no change 20%, worsening 30%

1 month improvement 63%, no change 12%, worsening 25%

Herman (2015), Rao (2016)

QLQ-PAN26

4–6 weeks improvement 100%

4 months return to baseline 100%

Hoyer (2005)

CTCAE

Baseline 54% pain ≥ 2

2 weeks 71% pain ≥ 2

3 months 94% pain ≥ 2 80% on morphine

Later on some transient improvement

Ji (2020)

NRS

Baseline 4.6 ± 1.3

4 weeks 2.5 ± 2.1

2 months3.0 ± 2.4

3 months3.1 ± 2.4

Jumeau (2018)

CTCAE

1 month improvement 36%, worsening 14% (of initially pain-free)

Liauw (2020)

NRS

8/15 patients had pain before SBRT, 5/8 (63%) had pain response after SBRT

Macchia (2012)

VAS

4 weeks improvement 44% (reduction of pain medication 22%)

Ryan (2018)

unknown

3 months improvement 73%

Shen (2010)

VAS

3 months improvement 100%

Tozzi (2013)

NRS

1 month improvement 100% (64% analgesics suspended, 27% analgesics reduced by 50%, 9% analgesics reduced by 20%), worsening 10% (of initially pain-free)

  1. CTCAE common terminology criteria for adverse events, NRS numerical rating scale for pain, QLQ-C30 quality of life questionnaire for cancer patients, QLQ-PAN26 quality of life questionnaire for pancreatic cancer patients, VAS visual analog scale for pain